Last reviewed · How we verify
d-methylphenidate
d-methylphenidate, marketed by the University of Cincinnati, is an established treatment in its class. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in the lack of disclosed primary indication and revenue data, which may limit strategic planning and investor confidence.
At a glance
| Generic name | d-methylphenidate |
|---|---|
| Also known as | Focalin |
| Sponsor | University of Cincinnati |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
- The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (PHASE4)
- Benefits of ADHD Treatment in Detained People (PHASE3)
- Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease (PHASE1)
- A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
- Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia (NA)
- The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
- Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |